New GLP-1 Agonist Retatrutide Undergoes Clinical Trials | Retatrutide News

Retatrutide, a new GLP-1 agonist by Eli Lilly, is in clinical trials for weight management and metabolic disorders. The trials aim to evaluate its effic...
Clinical Trials · October 9, 2026